CN-121975690-A - Lactobacillus plantarum with high ACE inhibition activity and application thereof

Abstract

The invention discloses lactobacillus plantarum with high ACE inhibition activity and application thereof, and belongs to the field of microbial medicines. The lactobacillus plantarum is classified and named Lactiplantibacillus plantarum P and preserved in China Center for Type Culture Collection (CCTCC) No. M20252435, and the 16S rDNA gene sequence is shown as SEQ ID No. 3. The lactobacillus plantarum provided by the invention is gram-positive bacteria, has high ACE (angiotensin converting enzyme) inhibition activity, better antioxidant capacity, better acid and bile salt resistance, and excellent automatic agglutination capacity and antibacterial performance, can achieve the effect of reducing blood pressure to a certain extent, and can be widely applied to the production of foods, health-care products, medicines and the like.

Inventors

• XU HENGYI
• JIA TIANTIAN
• DAI WEN
• GUO JIAJUN
• WANG YUCHENG
• WANG ZHICONG
• HUANG HAISHENG
• ZHANG MINGLIANG
• JIANG XINYU

Assignees

• 南昌大学

Dates

Publication Date

20260505

Application Date

20260130

Claims (10)

1. 1. A lactobacillus plantarum is characterized in that the lactobacillus plantarum is classified and named Lactiplantibacillus plantarum P517 and is preserved in China center for type culture collection, and a 16S rDNA gene sequence with the preservation number of CCTCC NO: M20252435,Lactiplantibacillus plantarum P517 is shown as SEQ ID NO: 3.
2. 2. The lactobacillus plantarum according to claim 1, wherein the strain is cultured in a solid MRS medium at 37 ℃ for 24-36 hours while maintaining a pH of 2.9-3.3.
3. 3. The lactobacillus plantarum according to claim 2, wherein 15g of agar powder and 10g of CaCO 3 are additionally added to the MRS solid culture medium.
4. 4. The lactobacillus plantarum of claim 2, wherein the automatic agglutination ability of the strain after 5h of cultivation is 72.79 ±1.61%.
5. 5. The lactobacillus plantarum according to claim 1, wherein the inhibition rate of the strain to ACE enzyme is 98.13+/-0.62%, the DPPH free radical scavenging capacity is 71.06+/-0.83%, and the reduction equivalent is 848.06 +/-7.33 mu mol/L based on vitamin C.
6. 6. The lactobacillus plantarum of claim 1, wherein the strain is isolated from faeces of a healthy adult population.
7. 7. Use of the lactobacillus plantarum of claim 1 in the preparation of food or health care products.
8. 8. Use of lactobacillus plantarum according to claim 1 for the preparation of a antihypertensive drug.
9. 9. Use according to claim 7 or 8, characterized in that the effective concentration of lactobacillus plantarum according to claim 1 in food or health products or antihypertensive drugs is 10 8 -10 9 CFU/mL.
10. 10. A probiotic preparation comprising at least one of a live bacterium, an inactivated bacterium, an extracellular metabolite or an intracellular extract of lactobacillus plantarum according to claim 1.

Description

Lactobacillus plantarum with high ACE inhibition activity and application thereof Technical Field The invention relates to the field of microbial medicines, in particular to lactobacillus plantarum with high ACE inhibition activity and application thereof. Background Hypertension is one of cardiovascular diseases seriously jeopardizing human health, and Angiotensin Converting Enzyme (ACE) plays a key regulatory role in the blood pressure regulating process, so the development of ACE inhibitors has become a research hotspot in the fields of functional foods and medicines. At present, although the chemical synthesized ACE inhibitor has remarkable antihypertensive effect, adverse reactions such as cough, angioneurotic edema and the like are often accompanied in clinical application, and the medication compliance and the medication safety of patients are seriously affected. Based on this, the search for natural, safe and efficient ACE inhibitors is becoming an important and urgent need for research in the current relevant fields. In recent years, it has been found that microorganisms of the genus Lactobacillus, in particular Lactobacillus plantarum, can be metabolized during fermentation to produce bioactive peptides having ACE inhibitory activity. The ACE inhibitor from probiotics not only has potential antihypertensive effect, but also can synchronously regulate the microecological balance of human intestinal tracts, has obviously better safety than chemical synthesis inhibitors, and has wide application prospect in the fields of functional foods, health-care products and pharmaceutical preparations. The prior researches show that the ACE inhibition activities of lactobacillus are strongest, and the ACE inhibition activities of bifidobacterium are lower, so that lactobacillus strains become a core research object for screening natural ACE inhibitors. Although various researches on lactobacillus strains are reported, lactobacillus plantarum strains with high ACE inhibition activity still have relatively lack of resources in the prior art, and the activity levels of different strains are uneven, so that the efficient industrialized application of the lactobacillus plantarum strains in blood pressure reduction functional products is greatly limited. After most lactobacillus strains are cultured in a fermentation MRS culture medium, the ACE inhibition rate of the supernatant is only 50%, and the lower inhibition activity leads to difficulty in meeting the actual requirement of functional products on the antihypertensive effect, so that the application scene is limited. Other reported high-activity lactobacillus strains, or the activity level thereof, still have room for improvement, or fermentation systems rely on specific matrix assistance, which is difficult to realize universal application. As mentioned in the published researches, the ACE inhibition activity of a product obtained by fermenting a whey protein system of Pediococcus SDL1414 is 84.7%, the activity of the strain depends on whey protein as a specific substrate, the activity is difficult to guarantee in a fermentation system without a specific protein matrix, the ACE inhibition rate of a product obtained by fermenting milk by using American lactobacillus K44 is 96.33%, the ACE inhibition rate of lactobacillus helveticus WH 2580 is 97.10%, although the activity is higher, the two are lactobacillus or lactobacillus helveticus strains and are not lactobacillus plantarum, the fermentation system is dependent on a dairy matrix, the dairy product provides a sufficient protein source for lactobacillus fermentation, and the activity of the product is easier to induce to produce ACE inhibitory peptide in theory, but the activity performance of the product in a general fermentation matrix is not clear. In addition, the ACE inhibition rate of a product obtained by fermenting goat milk by lactobacillus NK9 is 66.99%, the ACE inhibition rate of lactobacillus rhamnosus HCS01-013 detected by an ACE kit is 61.54%, the highest ACE inhibition activity of lactobacillus fermentum 187 detected by taking HHT as a substrate is only 43.29%, the strain or the activity level is low, or the detection substrate and the fermentation substrate have specificity, and the application limitation exists. In the prior art, most of the research on the ACE inhibitory activity of lactobacillus is focused on fermented dairy products, and the system can promote the generation of active peptide due to the sufficient protein matrix, but the screening report of high-activity strains of lactobacillus plantarum in a general fermentation matrix (such as MRS culture medium) is less, and the ACE inhibitory activity of the reported strains still has room for improvement. At the same time, single ACE inhibition may not achieve a good blood pressure lowering effect. Therefore, the novel lactobacillus plantarum strain which still has stable and high-efficiency ACE inhibition activity in a general ferm